Discovery of first-In-Class lead drug candidates for the treatment of multidrug resistant bacteria
Infection is one of the top 10 causes of death globally, responsible for 700 000 deaths annually. Mortality due to antimicrobial resistant infections is predicted to rise to above 10 million deaths per year by 2050. The global economic burden of such a rise in mortality and morbidity is estimated to be $100 trillion. Unfortunately, since 1980, no new antibiotic drug class has been discovered. Only limited therapeutic options are effective against the antibiotic resistant bacteria. As part of the global efforts to combat multidrug resistant bacteria, a group of novel molecules with unique chemical scaffolds were designed and synthesized at the Sharjah institute for medical research, University of Sharjah. We conclude that our discovered novel compounds are promising lead drug candidates for treating multidrug resistant infections. These compounds will be tested on experimental animals, followed by clinical trials to explore the possibility of using them as a new class of antibiotics to treat infections.
Taleb Al-Tel received his BS in Chemistry and Chemical Technology in 1987, MS in Natural Product Chemistry in 1990 from the faculty of Chemistry, Jordan University and Pennsylvania State Uni- versity, and PhD in 1995 from Tuebingen University-Germany followed by an NIH Postdoctoral Fellowship under the supervision of Professor Scott Sieburth, (Synthesis of Antiviral Lead drug candi- dates) at State University of New York. In 2003 he was appointed as a visiting associate professor at Duke Chemistry Department, North Carolina. Al-Tel joined Transtech Pharma-USA A Drug Discovery and Development Company from 2004 to 2007 as principal scientist and promoted to a Team Leader for Drug discovery groups (antiviral, anticancer, Obesity and Alzheimers). In 2007, he joined the col- lege of pharmacy-University of Sharjah in the United Arab Emirates as associate professor of organic medicinal chemistry then promoted to Professor in 2013.
Scale up of InnoDent tooth enamel regeneration technology for eliminating traditional dental drill & fill approach
90% of IsDB member countries’ population have some sort of tooth decay that is often left untreated at early stages, leading to health complications in future. We are searching for additional funding for commercialization of our technology in the ISDB member countries to make a difference to millions of people that lack access to affordable innovative healthcare technologies due to either (i) absence of enamel regeneration technology in their home country, or due to (ii) economical reasons that are based on too expensive dental service costs. In this project, we plan to address this issue by producing on a mass scale new products based on our technology, registering them in target ISDB MCs, and establishing a self-sustainable marketing & distribution supply chain of our technology by training local dentists and signing dealership agreements with local dental suppliers. This will allow us to achieve our main objective – to bring the affordable and effective technology to combat early tooth decay without a dentist drill & help children have caries-free life.
Baur Aituov graduated from University of York, UK with BSc Genetics in 2009. While at York, he was awarded “Top 80 the Highly Achievable UK Under- graduates” Certificate from Gatsby Foundation. After completing his PhD at Eurasian National University, he worked as a researcher at Nazarbayev University in Kazakhstan and Sanford-Burnham Research Institute in San Diego, USA. Currently he is the Founder of InnoDent startup company that develops non-in- vasive dental caries treatment approach based on natural regeneration process of amelogenin proteins. Technology has been patented, two products have now entered the market of Ukraine, Russia, Kazakhstan.
Maintaining medical equipment such as MRI, CT-Scan & X-Ray is difficult and expensive. Medical device manufactures lose millions of dollars due to warranty liability. Hospitals and clinics can’t afford for equipment to sit idle. Inspector is a real time IoT device, linked to the cloud, that monitors medical imaging devices. Uses AI deep learning technology to predict when and how the devices will stop working. Alarm system for service engineers and hospital management. Alerts via SMS and e-mail for all issues that cause malfunction and expensive repair. Already has GE as a customer and has been installed successfully in Egypt, Nigeria, Kenya, South Africa, KSA, UAE, Malaysia, Singapore, Turkey, Tunisia, Algeria and India, with 1000 devices already sold.
Tamer Ahmed is a serial entrepreneur, a researcher and a self-described geek. Has more than 20 years of experience in the telecommunication field and has worked for Sprint (USA) and Orange (Egypt). Had led many teams to achieve world-rec- ognized products like Internet for all, the winner of best telecommunication service in Africa-Com 2012. Tamer led the first technical team in Orange Major Service Center in 2004 and was able to handle the global operations for installation support, leading the center to grow from less than 100 team members to more than 1500 members. Tamer had founded 6 startups in the technology domain, two of them were in the IoT domain including BioBusiness, the latest successful IoT for medical equipment startup.